Posted by Michael Wonder on 15 Jul 2025
Vertex announces broad reimbursement agreement with NHS England for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) an innovative once daily CFTR modulator for the treatment of cystic fibrosis
14 July 2025 - All eligible people with cystic fibrosis in England can now benefit from this medicine -
Vertex Pharmaceuticals announced today that it has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis medicine Alyftrek (deutivacaftor/tezacaftor/vanzacaftor). This agreement comes as NICE has issued a positive final draft recommendation for this medicine.
